Objectives: To report the treatment outcomes of patients with extrinsic ureteral obstruction treated with metallic stents and to identify the factors predicting stent failure. Methods: A total of 52 patients with extrinsic ureteral obstruction as a result of malignancy (66 ureters) were treated with metallic stents (Resonance â ) and included in the study. The median observation period was 118 days.
Introduction
Ureteral obstruction caused by extrinsic compression as a result of benign or malignant diseases is an important clinical condition that must be treated by a urologist. MUO has been reported to be an indicator of poor prognosis, and the median life expectancy is generally <1 year in patients with metastatic cancer causing ureteral obstruction. 1, 2 Additionally, renal dysfunction as a result of urinary tract obstruction will adversely affect the treatment of cancer and can cause severe urinary tract infection. 3 Therefore, extrinsic ureteral obstruction is an oncological emergency. 3 Polymeric double J stents or nephrostomy have been the most common treatments of ureteral obstruction; however, the problem of the high occlusion rate in polymeric stents is yet to be resolved. [4] [5] [6] [7] [8] Although nephrostomy for relieving obstructions has a high technical success rate, one of the problems of nephrostomy is deterioration in the patients' quality of life. Recently, an increasing number of cases with extrinsic ureteral obstruction are being treated with metallic stents. The Resonance â stent (Cook Medical, Bloomington, IN, USA) is a continuous, unfenestrated all-metal double-pig tail ureteric stent with no end or side holes, and has an internal safety wire welded to both the closed ends. It is therefore deployed through a long sheath rather than over a guidewire. It is made of MP35N alloy, which is a composite of non-magnetic nickel-cobalt-chromium-molybdenum. This metal alloy is corrosion-resistant, magnetic resonance imaging-compatible, and has ultrahigh tensile strength.
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Since Borin et al. reported the initial experiences with the metallic stent, 10 it was approved in 2007 in many countries, and it became available in Japan from December 2014. Although there are several reports of adverse outcomes of metallic stents, many of those series included only a relatively small number of patients. 9, [11] [12] [13] [14] [15] [16] [17] [18] There are very few studies on extrinsic urinary tract obstruction as a result of malignant tumors, and fewer studies have analyzed the factors predicting stent occlusion.
We present a report of the treatment outcomes based on a relatively large retrospective cohort of 52 cases (66 ureters) with indwelling metallic stents against extrinsic ureteric obstruction as a result of malignancy, and identify an indicator of stent patency in these patients.
Methods
Between March 2015 and August 2016, metallic stents (Resonance â ) were placed in the ureters of 57 patients after being diagnosed with extrinsic ureteral obstruction. Among them, patients with ureteral invasion by urological cancers (bladder cancer and ureteral cancer) were excluded, because Goldsmith et al. suggested that urogenital cancer increases the risk of metallic stent failure, and patients with benign diseases (retroperitoneal fibrosis) were also excluded. 16 Finally, 52 cases (66 ureters) with extrinsic ureteral obstruction as a result of malignancies were included in the present study. The clinical characteristics of the patients are shown in Table 1 .
At Osaka City University Hospital, Osaka, Japan, all stents were placed in standard retrograde fashion using X-ray guidance, use of a guidewire, and a coaxial inner sheath and outer catheter under spinal anesthesia or local anesthesia. Then, retrograde pyelography was carried out to confirm the morphology of the renal pelvis and ureter. The metallic stents were inserted through the sheath after removing the guidewire and inner catheter. Follow-up imaging and blood sampling were carried out on the postoperative day 1 and at a 3-or 6-month interval in stable patients. Primary stent patency was defined as complete or partial resolution of hydronephrosis within 1 week. Partial resolution of hydronephrosis was defined as a decrease in hydronephrosis according to the Ellenbogen classification. 19 Stent failure was defined as unanticipated stent exchange or nephrostomy placement for signs or symptoms of recurrent ureteral obstruction (recurrent hydronephrosis or increasing serum creatinine). 16 When patients were alive >1 year after stent placement, the metallic stents were replaced.
Technical success was defined as insertion of a stent into the proper position without immediate complications. The survival rate in cases of ureteral obstruction as a result of malignancies was calculated using the Kaplan-Meier method. The relationship between the preoperative serum creatinine level and the stent occlusion, and the relationship between the change of hydronephrosis and the decrease rate of creatinine were analyzed using unpaired t-tests (Welch's test). The log-rank test was used to evaluate the relationship between the causes of ureteral obstruction, obstructed sites, obstructed sides and the patency rate. Cox proportional stepwise multivariate analysis was used to evaluate the association between these variables and stent failure.
All P-values were two-sided, and a value of <0.05 was considered statistically significant. Statistical analysis was carried out using Microsoft Excel (Microsoft, Redmond, WA, USA).
Permission to access the database for review of the medical records of these patients was approved by the local research ethics committee at Osaka City University (approval number 3440). All procedures carried out in studies involving human participants were in accordance with the ethical standards of the institution, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Results
The median observation period was 118 days (range 1-540). The baseline characteristics of patients are shown in Table 1 . All four cases of urogenital cancer developed extrinsic ureteral obstruction as a result of lymph node metastasis (not direct invasion or intrinsic obstruction). Four cases were switched from polymeric to metallic stents. The median survival time of 52 patients with MUO was 210 days, and just six cases (11.5%) were still alive >1 year later (Fig. 1) . There was one case in which the metallic stent could not be inserted into the ureter as a result of severe ureteral stricture; the technical success rate was 98.1% (51 patients). Hydronephrosis did not improve in three patients (six ureters) within 1 week; the primary patency rate was 90.9% (60 ureters). The stent patency rate was 86.0% at 6 months and 60.0% at 1 year (Fig. 2) . Eight patients (15.4%) underwent nephrostomy as a result of stent failure.
Next, we carried out statistical analyses to identify the clinical features that could cause stent failure. We did not see any difference in the stent patency rate among patients with abdominal dissemination, lymph node metastasis and direct compression by tumor (Fig. 3) . However, the occlusion rate of bilateral obstructed cases was significantly higher than that of unilateral cases, and this was an independent factor in the Cox proportional stepwise multivariate analysis ( Fig. 4 ; Table 2 ). There was no relationship between stent occlusion Total n = 52.
and preoperative serum creatinine level (treatment success: 2.00 AE 2.46 mg/dL, failure: 2.23 AE 0.87 mg/dL, P = 0.590), and obstructed ureteral portions were not related to stent occlusion (Fig. 5) . The decrease rate of serum creatinine was À0.587 AE 0.173 mg/dL in success cases, and +0.126 AE 0.227 mg/dL in failure case, respectively. However, there was no relationship between the change of hydronephrosis and the decrease rate of creatinine. Four cases (7.4%) of gross hematuria were observed as complications after stent placement, and symptoms of bladder irritation were confirmed in two cases (3.7%), without any need for anticholinergic medication. There was no emergency patient visit as a result of urinary tract infections and stentrelated symptoms.
Discussion
Metallic stent has been used worldwide; however, previous studies have included a relatively small cohort, and very few studies have analyzed individual situations associated with ureteral obstruction. Thus, we examined the treatment outcomes of metallic stents for MUO in a relatively large patient cohort, and carried out an analysis on predicting the relationship between stent failure in patients with MUO and the patients' situations. The present results showed that the treatment success rate for extrinsic obstruction cases as a result of malignant tumor was 86.0% at 6 months and 60.0% at 1 year; these results were superior to those of previous reports.
11,15-17 The incidence of stent failure was 15.4%, which is also superior to that of conventional polymeric stents (25-40%), which typically require nephrostomy. 20 Because the metallic stent has a coiled wire structure, it can maintain patency and urine drainage even under strong extrinsic compression. Another disadvantage of a polymeric stent is the need for changing it periodically every 3-6 months, whereas a metallic stent can remain in situ for 12 months before requiring a replacement. Considering that the median survival time with extrinsic ureteral obstruction as a result of malignant tumor is <12 months, there is a high possibility that stent replacement is unnecessary during such patients' lifetimes.
1,2 All these findings make it clear that metallic stent is the first choice for extrinsic ureteral obstruction as a result of MUO.
In contrast, it has been found that only a small number of patients experienced failure of metallic stent as well as polymeric stent in the present study. The prior studies have assessed the risk factors associated with metallic stent failure ( Table 3) . Brown et al. mentioned that stent occlusion appears to be increased in patients with postoperative urinary tract infection. 12 Wang et al. 15 and Li et al. 18 reported that patients who received radiotherapy had a higher failure rate after metallic stent insertion. Li et al. 18 and Goldsmith et al. 16 showed that gynecological malignancies and invasion of prostate cancer in the bladder significantly increases the risk of failure in each study. However, these reports are based on small patient cohorts and there is room for further investigation. Only Chow et al. investigated the radiological features as possible risk factors for stent failure based on a relatively large cohort. 17 The study by Chow et al. provides evidence that abdominal ureteral obstruction and lymphatic metastasis around the ureter were associated with shorter functional duration. 17 In the present study, the obstructed portion of ureter and lymph node metastasis did not have a significant effect on metallic stent failure. At our hospital, six out of eight cases of stent failure were extrinsic ureteral obstruction as a result of peritoneal dissemination of gastric cancer. Although cases with gastric cancer were more likely to develop stent failure than those with other cancers, it is important to consider that there might be a causal relationship between ureteral obstruction as a result of disseminated cancer and occlusion of the metallic stent, although we did not find statistical significance for this observation. Park et al. 21 and Kamiyama et al. 22 reported that the polymeric ureteral stent is less effective when disseminated cancer, such as gastric tumor, disturbs a wide range of ureteral peristaltic movements. We further examined whether cancer dissemination, lymph node metastasis or direct tumor invasion were attributable to the cause of occlusion, but we found no correlation between occlusion and these factors. In the present study, the occlusion rate of bilateral cases was significantly higher than that of unilateral cases. In cases where bilateral obstruction occurred, the disease progression was severe and it was likely to induce stent occlusion.
There was no relationship observed between preoperative serum creatinine levels and stent occlusion. Serum creatinine is largely affected by the general condition and/or contralateral renal function, and might not reflect the stent patency rate. Furthermore, for the same reason, no relationship between the change of hydronephrosis and the decrease rate of creatinine was shown.
Complications of an indwelling metallic stent include symptoms of bladder irritation and macrohematuria, which might affect a patient's quality of life. At our hospital, sustained macrohematuria was seen in just 7% of these patients. Complications of the metallic stent are comparable with those of the conventional polymeric stent. However, visibility on X-ray imaging is better with metallic stents, and a slight halation will not be a problem on computed tomography scan. Resonance is formed by a tight spirally coiled metal wire, and have a high flexibility. Because of these favorable features, the rate of bladder irritation might be relatively low.
No adhesion of calculi was seen in the six exchanged metal stents. It is said that it is difficult for stones to stick to metallic stents. Long-term observation will be necessary to see a biocompatibility and ureteral artery fistula formation.
The present study was a retrospective study, and thus had certain limitations. In this study, we could not compare treatment outcomes of the metallic stent and polymeric stent, and stent-related symptoms were not evaluated by using the ureteric stent symptoms questionnaire. Further studies are required to clarify these points.
In summary, the present results provide a valid argument that a metallic stent is appropriate for patients with extrinsic ureteral obstruction without severe complications. It seems reasonable that the metallic stent should be preferred for extrinsic ureteral obstruction as a result of MUO. Further studies are required to optimize the relationship between stent occlusion and causes of ureteral obstruction.
